7 Blood Clots Deaths After Administration of AstraZeneca Vaccine for Covid-19 In the UK

Researches Are Ongoing, Although There Is A Possibility of Risk of Unusual Clotting of Blood Resulting in Mortality

Seven individuals have reportedly died as they soon started developing blood clots after being administered with the AstraZeneca vaccine in the United Kingdom, which has been confirmed by the medicines regulating authorities of the country. In total, it has been observed that 30 individuals out of 18 million doses administered until March 24 have caused these blood clots.

Formation of blood clots linked with COVID-19 vaccine

It is yet to be confirmed that the adverse body reaction of the formation of blood clots is either just a coincidence in the reported number of cases up till now, or it is a genuine reaction of the AstraZeneca vaccine in certain individuals.

According to the Medicines and Healthcare Products Regulatory Agency, the benefits of the administration of the AstraZeneca vaccine are in continuous succession to outweigh the possible side effects of the drug against coronavirus pandemic. Both the European Medicines Agency and the World Health Organization are in agreement with this conclusion.

A spokesperson for the pharmaceutical firm that developed the AstraZeneca vaccine stated that the high priority of their firm is to keep the safety of the patient. However, this concern has to lead the other countries, including Canada, the Netherlands, France, and Germany, towards restricting the administration of AstraZeneca vaccine to older individuals only.

The data report released on Friday by the MHRA has shown that 22 cases have been reported which have been diagnosed with cerebral venous sinus thrombosis (CVST), which is a type of blood clot in the brain. This was also accompanied by the reduction in the number of platelets available in the blood, which are broken red blood cell particles used by the body for the formation of blood clots.

The MHRA has also been able to find other problems related to the clotting factor in eight individuals, along with low platelet count. It was later reported by the MHRA that seven individuals sadly passed away due to this persisting problem.

According to the chief executive of MHRA, Dr. June Raine, the benefits in the prevention of coronavirus infection and its complications still continues to outweigh the potential risk factors that are currently being observed after administration of AstraZeneca vaccine in the general population, and the public should continue to get the dose for the vaccine when they are invited to do so by the government.

Research investigation for AstraZeneca vaccine

Several investigations are being conducted by researchers to determine the relationship between the administration of AstraZeneca vaccine and the formation of blood clots. In the last week of March, the European Medicines Agency has reported that it is yet to be scientifically and experimentally proven, but there is a major possibility that the AstraZeneca vaccine is causing blood clots in certain individuals, which, if left untreated, could result in mortality.

There are two issues that are currently raising suspicion. First is the unusual nature of the formation of blood clots, with the reduction in the number of platelets in blood along with rare antibody levels, which has been found to be related to several clotting disorders.

According to the Professor from UCL Institute of Neurology, David Werring, that after this observation, there has been a rise in the possibility that the AstraZeneca vaccine could be a factor in the usual and rare cases of developing CVST, though it is yet to be found, due to which more amount of research is required.

Another possible issue with the AstraZeneca vaccine is its difference in development with the Pfizer-BioNTech vaccine. There have been two cases reported diagnosed with CVST after administration of Pfizer vaccine in the United Kingdom, after more than 10 million doses have been administered, but no reduction in platelet levels have been observed.

However, there is still uncertainty regarding the common occurring of blood clots. The estimated range observed from two cases per million individuals per year to nearly 16 in one million population in normal times, and the COVID-19 infection has also been linked to abnormal blood clotting, which is making the formation of blood clots more common.

31 CVST cases have been reported in Germany along with nine mortalities out of 2.7 million administration of doses of a viable coronavirus vaccine, mostly in young children and middle-aged women of the country.

Similar data is yet to be received regarding the affected individuals in the United Kingdom due to the administration of AstraZeneca vaccine, as it is yet to be published, but it is expected that a wider mix of individuals has been affected.

Read also Double Mutant Coronavirus Variant Detected In India